Preview

Артериальная гипертензия

Расширенный поиск

Полиморфизм гена Apo E у пациентов с метаболическим синдромом и когнитивными расстройствами

https://doi.org/10.18705/1607-419X-2012-18-5-421-428

Полный текст:

Аннотация

Цель исследования — определение частот аллельных вариантов, обусловленных полиморфизмом гена Apo E у лиц с метаболическим синдром (МС) и когнитивными нарушениями (КН). Материалы и методы. Обследованы 54 человека с использованием антропометрии, биохимического анализа крови (глюкоза, липидный спектр), молекулярно-генетического анализа (полимеразная цепная реакция, полиморфизм длин рестрикционных фрагментов) и нейропсихологических тестов. Выводы. Аллельный вариант s4 гена Apo E является неблагоприятным фактором, способствующим развитию КН, депрессии, тревожных расстройств. Носительство аллеля s2 является протективным фактором в отношении развития депрессии.

Об авторах

И. Б. Зуева
ФГБУ «Федеральный Центр сердца, крови и эндокринологии им. В.А. Алмазова» Минздравсоцразвития РФ
Россия


А. С. Улитина
ФГБУ «Федеральный Центр сердца, крови и эндокринологии им. В.А. Алмазова» Минздравсоцразвития РФ; ГБОУ ВПО «Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздравсоцразвития РФ
Россия


Д. Н. Гораб
ГБОУ ВПО «Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздравсоцразвития РФ; Санкт-Петербургский академический университет, научно-образовательный центр нанотехнологий Российской академии наук
Россия


М. В. Москаленко
ФГОУ ВПО «Санкт-Петербургский государственный университет»
Россия


М. В. Дубина
ГБОУ ВПО «Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздравсоцразвития РФ; Санкт-Петербургский академический университет, научно-образовательный центр нанотехнологий Российской академии наук
Россия


Список литературы

1. Peila R., White L.R., Masaki K., Petrovitch H., Launer L.J. Reducing the risk of dementia: Efficacy of long-term treatment of hypertension // Stroke. — 2006. — Vol. 37. — P. 1165-1170.

2. Зуева И.Б., Ванаева К.И., Санец Е.Л. и др. Взаимосвязь факторов сердечно-сосудистого риска с когнитивными функциями у пациентов среднего возраста // Артериальная гипертензия. — 2011. — Т. 17, № 5. — С. 432-441.

3. Kalaria R. Similarities between Alzheimer’s disease and vascular dementia // J. Neurol. Sci. — 2002. — Vol. 203-204. — P. 29-34.

4. Launer L.J. Demonstrating the case that AD is a vascular disease: Epidemiologic evidence // Ageing Res. Rev. — 2002. — Vol. 1, № 1. — Р. 61-67.

5. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) // J. Am. Med. Assoc. — 2001. — Vol. 285, № 19. — P. 2486-2497.

6. Grundy S.M., Cleeman J.I., Daniels S.R. et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement // Circulation. — 2005. — Vol. 112, № 17. — P. 27352752.

7. Sattar N., Gaw A., Scherbakova O. et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study // Circulation. — 2003. — Vol. 108, № 4. — P. 414-419.

8. Laaksonen D.E., Lakka Н.М., Niskanen L.K., Kaplan G.A., Salonen J.T., Lakka T.A. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study // Am. J. Epidemiol. — 2002. — Vol. 156, № 11. — P. 1070-1077.

9. Elias МТ., Sullivan L.M., D’Agostino R.B. et al. Framingham stroke risk profile and lowered cognitive performance // Stroke. — 2004. — Vol. 35, № 2. — P. 404-409.

10. Kivipelto М., Ngandu T., Fratiglioni L. et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease // Arch. Neurol. — 2005. — Vol. 62, № 10. — P. 1556-1560.

11. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease // Trends. Neurosci. — 1994. — Vol. 17, № 12. — P. 525-530.

12. Strittmatter W.J., Saunders AM., Schmechel D. et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease // Proc. Natl. acad. Sci USA. — 1993. — Vol. 90, № 17. — P. 1977-1981.

13. Davignon J., Gregg R.E., Sing S.F. Apolipoprotein E polymorphism and atherosclerosis // Arteriosclerosis. — 1988. — Vol. 8, № 1. — P. 1-21.

14. Terry J.G., Howard G., Mercuri М., Bond М.&, Crouse J.R. 3rd. Apolipoprotein E polymorphism is associated with segment-specific extracranial carotid artery intima-media thickening // Stroke. — 1996. — Vol. 27, № 10. — P. 155-175.

15. Vauhkonen I., Nisknen L., Ryynanen М. et al. Divergent association of apolipoprotein E polymorphism with vascular disease in patients with NIDDM and control subjects // Diabet. Med. — 1997. — Vol. 14, № 9. — P. 748-756.

16. Cattin L., Fisicaro М., Tonizzo М. et al. Polymorphism of the apolipoprotein E gene and early carotid atherosclerosis defined by ultrasonography in asymptomatic adults // Arterioscler. Thromb. Vasc. Biol. — 1997. — Vol. 17, № 1. — P. 91-97.

17. Hannon O., Girerd X., Luong V. Association between the apolipoprotein E polymorphism and arterial wall thickness in asymptomatic adults // J. Hypertens. — 2000. — Vol. 18, № 4. — P. 431-436.

18. Hillen T., Nieczaj R., Munzmerg H. et al. Carotid atherosclerosis, vascular risk profile and mortality in a population-besed sample of functionally healhty elderly subjects: the Berlin Ageing Study // J. Intern. Med. — 2000. — Vol. 247, № 6. — P. 679-688.

19. Murphy G.M. The APOE epsilon4 allele is associated with decline on delayed recall performance in community dwelling older adults // J. Am. Geriatr. Soc. — 1998. — Vol. 46, № 12. — P. 1493-1498.

20. Yaffe K., Cauley J., Sands L., Browner W. Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women // Arch. Neurol. — 1997. — Vol. 54, № 9. — P. 1110-1114.

21. Bunce D., Fratiglioni L., Small B.J., Winblad B., Back-man L. APOE and cognitive decline in preclinical Alzheimer disease and non-demented aging // Neurology. — 2004. — Vol. 63, № 5. — P. 816-821.

22. Pendleton N., Payton A., van den Boogerd E.H. et al. Apolipoprotein E genotype does not predict decline in intelligence in healthy older adults // Neurosci. Lett. — 2002. — Vol. 324, № 1. — P. 74-76.

23. Small B.J., Graves A.B., McEvoy C.L., Crawford F.C., МШЫп М., Mortimer J.A. Is APOE-s4 a risk factor for cognitive impairment in normal aging? // Neurology. — 2000. — Vol. 54, № 11. — P. 2082-2088.

24. Winnock М., Letenneur L., Jacqmin-Gadda H., Dallon-geville J., Amouyel P., Dartigues J.F. Longitudinal analysis of the effect of apolipoprotein E epsilon4 and education on cognitive performance in elderly subjects: the PAQUID study // J. Neurol. Neurosurg. Psychiatry. — 2002. — Vol. 72, № 6. — P. 794-797.

25. Zhao J.H., Brunner E.J., Kumari М. et al. APOE polymorphism, socioeconomic status and cognitive function in mid-life-the Whitehall II longitudinal study // Soc. Psychiatry Psychiatr. Epidemiol. — 2005. — Vol. 40, № 7. — P. 557-563.

26. Благосклонная Я.В., Шляхто Е.В., Бабенко А.Ю. Эндокринология: Уч. для мед. ВУЗов. — Спб.: СпецЛит, 2004. — 398 с.

27. Mahley R.W., Innerarity T.L., Rall S.C., Weisgraber K.H. Plasma lipoproteins: apolipoprotein structure and function // J. Lipid Res. — 1984. — Vol. 25, № 12. — Р. 1277-1294.

28. Kolovou G., Damaskos D., Anagnostopoulou K., Cokkinos D.V. Apolipoprotein E gene polymorphism and gender // Ann. Clin. Lab. Sci. — 2009. — Vol. 39, № 2. — Р. 120-133.

29. Scott J., Knott T.J., Shaw D.J., Brook J.D.: Localization of genes encoding apolipoproteins CI, CII, and E to the p13-cen region of human chromosome 19 // Hum. Genet. — 1985. — Vol. 71, № 2. — Р. 144-146.

30. Weisgraber K.H., Rall S.C., Mahley R.W. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms // J. Biol. Chem. — 1981. — Vol. 256, № 17. — Р. 9077-9083.

31. Medina-Urrutia A.X., Cardoso-Saldana G.C., Zamora-Gonzalez J., Liria Y.K., Posadas-Romero C. Apolipoprotein E polymorphism is related to plasma lipids and apolipoproteins in Mexican adolescents // Hum. Biol. — 2004. — Vol. 76, № 4. — Р. 605-614.

32. Liang S., Pan M., Geng H.H. et al. Apolipoprotein E polymorphism in normal Han Chinese population: frequency and effect on lipid parameters // Mol. Biol. Rep. — 2009. — Vol. 36, № 6. — Р 1251-1256.

33. de-Andrade F.M., Larrandaburu M., Callegari-Jacques S.M., Gastaldo G., Hutz M.H. Association of apolipoprotein E polymorphism with plasma lipids and Alzheimer’s disease in a Southern Brazilian population // Braz. J. Med. Biol. Res. — 2000. — Vol. 33, № 5. — Р 529-537.

34. Mendes-Lana A., Pena G.G., Freitas S.N. et al. Apolipoprotein E polymorphism in Brazilian dyslipidemic individuals: Ouro Preto study // Braz. J. Med. Biol. Res. — 2007. — Vol. 40, № 1. — Р 49-56.

35. De Franca E., Alves J.G., Hutz M.H. Apolipoprotein E polymorphism and its association with serum lipid levels in Brazilian children // Hum. Biol. — 2004. — Vol. 76, № 2. — Р. 267-275.

36. Saidi S., Slamia L.B., Ammou S.B., Mahjoub T., Almawi W.Y. Association of apolipoprotein E gene polymorphism with ischemic stroke involving large-vessel disease and its relation to serum lipid levels // J. Stroke Cerebrovasc. Dis. — 2007. — Vol. 16, № 4. — Р 160-166.

37. Kumar P., Luthra K., Dwivedi M., Behl V.K., Pandey R.M., Misra A. Apolipoprotein E gene polymorphisms in patients with premature myocardial infarction: a case-controlled study in Asian Indians in North India // Ann. Clin. Biochem. — 2003. — Vol. 40, Pt. 4. — Р 382-387.

38. Pitsavos C., Choumerianou D.M., Skoumas J. et al. Apolipoprotein E polymorphism is not associated with lipid levels and coronary artery disease in Greek patients with familial hypercholesterolaemia // Clin. Exp. Med. — 2005. — Vol. 5, № 4. — Р 196-201.

39. Gottlieb M.G., Schwanke C.H., Santos A.F., Jobim P.F., Mussel D.P., da Cruz I.B. Association among oxidized LDL levels, MnSOD, apolipoprotein E polymorphisms, and cardiovascular risk factors in a south Brazilian region population // Genet. Mol. Res. — 2005. — Vol. 4, № 4. — Р 691-703.

40. Carmo M. M., Lima F.L., Rodrigues M.O., Albergaria I., Fonseca A. Influence of the APOE genotypes in some atherosclerotic risk factors // Acta Med. Port. — 2008. — Vol. 21, № 5. — Р. 433-440.

41. Kolovou G.D., Anagnostopoulou K.K., Kostakou P. et al. Apolipoprotein E gene polymorphism and obesity status in middle-aged men with coronary heart disease // In Vivo. — 2009. — Vol. 23, № 1. — Р 33-39.

42. Rosenberg R.N. The molecular and genetic basis of AD: the end of the beginning. The 2000 Wartenberg lecture // Neurology. — 2000. — Vol. 54, № 11. — P. 2045-2054.

43. Saunders A.M., Strittmatter W.J., Schmechel D. Association of apolipoprotein E allele e4 with late-onset familial and sporadic Alzheimer’s disease // Neurology. — 1993. — Vol. 43, № 8. — P. 1467-1472.

44. Deary I.J., Whiteman M.C., Pattie A. et al. Cognitive change and the APOE e4 allele // Nature. — 2002. — Vol. 418, № 6901. — P. 932.

45. Dik M.G.C., Jonker M.D., Comijs H.C. Memory complaints and APOE-4 accelerate cognitive decline in cognitively normal elderly // Neurology. — 2001. — Vol. 57, № 12. — P. 22172222.

46. Feskens E.J., Havekes L.M., Kalmjin S., de Knijff P., Launer L.J., Kromhout D. Apolipoprotein e4 allele and cognitive decline in elderly men // Br. Med. J. — 1994. — Vol. 309, № 6963. — P. 1202-1206.

47. Haan M.N., Shemanski L., Jagust W.J., Manolio T.A., Kuller L. The role of APOE e4 in modulating effects of other risk factors for cognitive decline in elderly persons // J. Am. Med. Assoc. — 1999. — Vol. 282, № 1. — P. 40-46.

48. Helkala E.L., Koivisto K., Hannien T. Memory function in human subjects with different apolipoprotein E phenotypes during a 3-year population-base study // Neurosci. Lett. — 1996. — Vol. 204, № 3. — P. 177-180.

49. Hofer S.M., Christensen H., Mackinnon A.J. Change in cognitive functioning associated with ApoE genotype in a community sample of older adults // Psychol. Aging. — 2002. — Vol. 17, № 2. — P. 194-208.

50. Hyman B.T., Gomez-Isla T., Brigg M. Apolipoprotein E and cognitive changes in an elderly population // Ann. Neurol. — 1996. — Vol. 40, № 1. — P. 55-66.

51. Mayeux R., Small S.A., Tang M.X. Memory performance in healthy elderly without Alzheimer’s disease: effects of time and apolipoprotein-E // Neurobiol. Ageing. — 2001. — Vol. 22, № 4. — P. 683-689.

52. O’Hara R., Yesavage J.A., Kraemer H.C. The APOE-e4 allele is associated with decline on delayed recall performance in community-dwelling adults // J. Am. Geriatr. Soc. — 1998. — Vol. 46, № 12. — P. 1493-1498.

53. Bartres-Faz D., Junqu C., Moral P. Apolipoprotein E gender effects on cognitive performance in age associated memory impairment // J. Neuropsychiatry Clin. Neurosci. — 2002. — Vol. 14. — P. 80-83.

54. Mortensen E.L., Hogh P. A gender difference in the association between APOE genotype and age related cognitive decline // Neurology. — 2001. — Vol. 57, № 1. — P. 89-95.

55. Juva K., Verkkoniemi A., Viramo P. APOE epsilon4 does not predict mortality, cognitive decline, or dementia in the oldest old // Neurology. — 2000. — Vol. 54, № 2. — P. 412-415.

56. Pendleton N., Payton A., van den Boogerd E.H. (2002) Apolipoprotein E genotype does not predict decline in intelligence in healthy older adults // Neurosci. Let. — 2002. — Vol. 324, № 1. — P. 74-76.

57. Small B.J., Graves A.B., McEvoy C.L., Crawford F.C., Mullan M., Mortimer J.A. (2000) Is APOE-e4 a risk factor for cognitive impairment in normal aging? // Neurology. — 2000. — Vol. 54, № 11. — P. 2082-2088.

58. Christensen H., Batterham F.J., Mackinnon A.J. et al. The association of APOE genotype and cognitive decline in interaction with risk factors in a 65-69 year old community sample // BMC Geriatrics. — 2008. — Vol. 8. — P. 1-10.

59. Greenwood P.M., Sunderland T., Friz J.L., Parasuraman R. Genetics and visual attention: selective deficits in healthy adult carriers of the epsilon 4 allele of the apolipoprotein E gene // Proceedings of the National Academy of Sciences of the United States of America. — 2000. — Vol. 97, № 21. — Р 1166111666.

60. Greenwood P.M., Lambert C., Sunderland T., Para-suraman R. Effects of apolipoprotein E genotype on spatial attention, working memory, and their interaction in healthy, middle-aged adults: results from the National Institute of Mental Health’s BIOCARD study // Neuropsychology. — 2005. — Vol. 19, № 2. — Р 199-211.

61. Peskind E.R., Li G., Shofer J. et al. Age and apolipoprotein E4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition // Arch. Neurol. — 2006. — Vol. 63, № 7. — Р. 936-939.

62. Albert M., Blacker D., Moss M.B., Tanzi R., McArdle J.J. Longitudinal change in cognitive performance among individuals with mild cognitive impairment // Neuropsychology. — 2007. — Vol. 21, № 2. — Р 158-169.

63. Skoog I., Gustafson D.: Update on hypertension and Alzheimer’s disease // Neurol. Res. — 2006. — Vol. 28. — P. 605-611.

64. Qiu C., Winblad B., Fastbom J., Fratiglioni L. Combined effects of APOE genotype, blood pressure, and antihypertensive drug use on incident AD // Neurology. — 2003. — Vol. 61, № 5. — P. 655-660.

65. Peila R., Rodriguez B.L., Launer L.J. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study // Diabetes. — 2002. — Vol. 51, № 4. — P. 1256-1262.

66. Hofman A., Ott A., Breteler М.М. et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam Study // Lancet. — 1997. — Vol. 349. — P. 151-154.

67. Slooter A.J., Tang М.Х., van Duijn CM. et al. Apolipoprotein E epsilon4 and the risk of dementia with stroke. A population-based investigation // J. Am. Med. Assoc. — 1997. — Vol. 277, № 9046. — P. 818-821.

68. Garcia-Pena C., Juarez-Cedillo T., Cruz-Robles D. et al. Depressive symptoms and APOE polymorphisms in an elderly population-based sample // Psychiatr. Genet. — 2010. — Vol. 20, № 5. — Р. 215-220.

69. Elovainio М., Puttonen S., Pulkki-Raback L. et al. Association ofthe apolipoprotein E gene, its promoter polymorphisms and haplotypes with depressive symptoms. The Cardiovascular Risk in Young Finns Study // Neuropsychobiology. — 2008. — Vol. 58, № 2. — Р. 91-96.

70. Mauricio М., O’Hara R., Yesavage J.A. et al. A longitudinal study of apolipoprotein-E genotype and depressive symptoms in community-dwelling older adults // Am. J. Geriatr. Psychiatry. — 2000. — Vol. 8, № 3. — Р. 196-200.


Для цитирования:


Зуева И.Б., Улитина А.С., Гораб Д.Н., Москаленко М.В., Дубина М.В. Полиморфизм гена Apo E у пациентов с метаболическим синдромом и когнитивными расстройствами. Артериальная гипертензия. 2012;18(5):421-428. https://doi.org/10.18705/1607-419X-2012-18-5-421-428

For citation:


Zueva I.B., Ulitina A.S., Ghorab D.N., Moskalenko M.V., Dubina M.V. Apo E gene polymorphism in patients with metabolic syndrome and cognitive disorders. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2012;18(5):421-428. (In Russ.) https://doi.org/10.18705/1607-419X-2012-18-5-421-428

Просмотров: 283


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1607-419X (Print)
ISSN 2411-8524 (Online)